Vaccine manufacturing facility design
Key Statistics
GSK Vaccines
14,300 sqm

GSK Vaccines is one of the world’s leading vaccine manufacturers and from its Belgium headquarters, it conducts research, development, production and sales activities. This project involved a greenfield bulk vaccine manufacturing facility within GSK Biologicals' Wavre site.

Do you have a Vaccine project? Talk to one of our experts.

Andy Rayner
Andy Rayner

Pharmaceutical Sector Director

The project

This project involved complex process and services design within a densely packaged building. A fully integrated 3D model for all services was utilised from the BOD phase and this proved to be an essential design tool for the successful delivery of the project.

The new facility is a single product facility focused on manufacturing whooping cough vaccine. The facility is classified as BL2 in the Fermentation area and meets FDA and EMEA regulatory requirements.

Located over five levels, the bulk manufacturing building consists primarily of a basement (including mezzanine), a production floor (including walk-on ceiling) and a plantroom floor, totalling 14,300 sqm of which there is approx 3,100 sqm of classified space.

One Team

With 500 workers speaking 18 languages on site at peak, construction, the 'One Team' culture established between the client, project team and the many construction contractors contributed enormously to the achievement of 1.25 million construction hours without an LTA.


The project was constructed concurrently with three other adjacent projects, which shared the same site. This involved significant coordination between projects to ensure the highest safety performance throughout project execution.

Andy Rayner

Pharmaceutical Sector Director